Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
RATIONALE: Phosphodiesterase type 5 (PDE5) inhibition has been proposed for the treatment for pulmonary arterial hypertension (PAH). OBJECTIVE: This study compared adding sildenafil, a PDE5 inhibitor, to conventional treatment with the current practice of adding bosentan, an endothelin receptor antagonist. METHODS: Twenty-six patients with PAH, idiopathic or associated with connective tissue disease, World Health Organization (WHO) functional class III, were randomized in a double-blind fashion to receive sildenafil (50 mg twice daily for 4 weeks, then 50 mg three times daily) or bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily) over 16 weeks. MEASUREMENTS: Changes in right ventricular (RV) mass (using cardiovascular magnetic resonance), 6-minute walk distance, cardiac function, brain natriuretic peptide, and Borg dyspnea index. MAIN RESULTS: When analyzed by intention to treat, there were no significant differences between the two treatment groups. One patient on sildenafil died suddenly. Patients on sildenafil who completed the protocol showed significant changes from baseline, namely, reductions in RV mass (-8.8 g; 95% confidence interval [CI], -2, -16; n = 13, p = 0.015) and plasma brain natriuretic peptide levels (-19.4 fmol x ml(-1); 95% CI, -5, -34; p = 0.014) and improvements in 6-minute walk distance (114 m; 95% CI, 67, 160; p = 0.0002), cardiac index (0.3 L x min(-1) x m(-2); 95% CI, 0.1, 0.4; p = 0.008), and systolic left ventricular eccentricity index (-0.2; 95% CI, -0.02, -0.37; p = 0.031). Bosentan improved 6-minute walk distance (59 m; 95% CI, 29, 89; n = 12, p = 0.001) and cardiac index (0.3; 95% CI, 0.1, 0.4; p = 0.008). CONCLUSIONS: Sildenafil added to conventional treatment reduces RV mass and improves cardiac function and exercise capacity in patients with PAH, WHO functional class III. Safety monitoring is important until more experience is obtained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D'Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., Kernis, J. T., et al. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-5-343 · Cited by 3,501
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary Hypertension
Rich, S., Kaufmann, E., & Levy, P. S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270203 · Cited by 1,550
Channick, R. N., Simonneau, G., Sitbon, O., Robbins, I. M., Frost, A., Tapson, V. F., Badesch, D. B., Roux, S., Rainisio, M., Bodin, F., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06250-x · Cited by 1,534
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Guanylyl Cyclases and Signaling by Cyclic GMP
Lucas, K. A., Pitari, G. M., Kazerounian, S., Ruiz-Stewart, I., Park, J., Schulz, S., Chepenik, K. P., & Waldman, S. A. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01457-1 · Cited by 1,224
Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy
McLaughlin, V. V., Shillington, A., & Rich, S. (2002) · Circulation · doi:10.1161/01.cir.0000029100.82385.58 · Cited by 1,213
MIYAMOTO, S., NAGAYA, N., SATOH, T., KYOTANI, S., SAKAMAKI, F., FUJITA, M., NAKANISHI, N., & MIYATAKE, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.9906015 · Cited by 1,154
Badesch, D. B., Tapson, V. F., McGoon, M. D., Brundage, B. H., Rubin, L. J., Wigley, F. M., Rich, S., Barst, R. J., Barrett, P. S., Kral, K. M., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-6-200003210-00002 · Cited by 1,075
Doppler echocardiographic index for assessment of global right ventricular function
Tei, C., Dujardin, K. S., Hodge, D. O., Bailey, K. R., McGoon, M. D., Tajik, A. J., & Seward, J. B. (1996) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(96)90476-9 · Cited by 979
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy
Takimoto, E., Champion, H. C., Li, M., Belardi, D., Ren, S., Rodriguez, E. R., Bedja, D., Gabrielson, K. L., Wang, Y., & Kass, D. A. (2005) · Nature Medicine · doi:10.1038/nm1175 · Cited by 903
Nagaya, N., Nishikimi, T., Uematsu, M., Satoh, T., Kyotani, S., Sakamaki, F., Kakishita, M., Fukushima, K., Okano, Y., Nakanishi, N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.8.865 · Cited by 876
Grothues, F., Moon, J. C., Bellenger, N. G., Smith, G. S., Klein, H. U., & Pennell, D. J. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.10.005 · Cited by 776
Self-citationBeraprost therapy for pulmonary arterial hypertension
Barst, R. J., McGoon, M., McLaughlin, V., Tapson, V., Oudiz, R., Shapiro, S., Robbins, I. M., Channick, R., Badesch, D., Rayburn, B. K., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00463-7 · Cited by 631
Survival with first-line bosentan in patients with primary pulmonary hypertension
McLaughlin, V. V., Sitbon, O., Badesch, D. B., Barst, R. J., Black, C., Galiè, N., Rainisio, M., Simonneau, G., & Rubin, L. J. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00054804 · Cited by 602
Cyclic GMP Phosphodiesterase-5: Target of Sildenafil
Corbin, J. D., & Francis, S. H. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13729 · Cited by 531
Primary pulmonary hypertension
Runo, J. R., & Loyd, J. E. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13167-4 · Cited by 521
Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function
Rybalkin, S. D., Yan, C., Bornfeldt, K. E., & Beavo, J. A. (2003) · Circulation Research · doi:10.1161/01.res.0000087541.15600.2b · Cited by 511
An echocardiographic index for separation of right ventricular volume and pressure overload
Ryan, T., Petrovic, O., Dillon, J. C., Feigenbaum, H., Conley, M. J., & Armstrong, W. F. (1985) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(85)80433-2 · Cited by 493
Sildenafil Inhibits Hypoxia-Induced Pulmonary Hypertension
Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A., & Wilkins, M. R. (2001) · Circulation · doi:10.1161/hc2901.093117 · Cited by 488
Self-citationEffect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension
Wilkens, H., Guth, A., König, J., Forestier, N., Cremers, B., Hennen, B., Böhm, M., & Sybrecht, G. W. (2001) · Circulation · doi:10.1161/hc3601.096826 · Cited by 392
Galiè, N., Hinderliter, A. L., Torbicki, A., Fourme, T., Simonneau, G., Pulido, T., Espinola-Zavaleta, N., Rocchi, G., Manes, A., Frantz, R., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00121-9 · Cited by 378
Moon, J. C. C., Lorenz, C. H., Francis, J. M., Smith, G. C., & Pennell, D. J. (2002) · Radiology · doi:10.1148/radiol.2233011181 · Cited by 294
Self-citationCombination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension
Hoeper, M. M., Faulenbach, C., Golpon, H., Winkler, J., Welte, T., & Niedermeyer, J. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00051104 · Cited by 268
Phosphodiesterase Type 5 as a Target for the Treatment of Hypoxia-Induced Pulmonary Hypertension
Sebkhi, A., Strange, J. W., Phillips, S. C., Wharton, J., & Wilkins, M. R. (2003) · Circulation · doi:10.1161/01.cir.0000074226.20466.b1 · Cited by 261
Self-citationSENZAKI, H., SMITH, C. J., JUANG, G. J., ISODA, T., MAYER, S. P., OHLER, A., PAOLOCCI, N., TOMASELLI, G. F., HARE, J. M., & KASS, D. A. (2001) · The FASEB Journal · doi:10.1096/fj.00-0538com · Cited by 228
Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase.
Thomas, M. K., Francis, S. H., & Corbin, J. D. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)77210-4 · Cited by 226
HANDLEY, A. J. (2001) · Heart · doi:10.1136/heart.86.1.1 · Cited by 222
Atrial Volume in a Normal Adult Population by Two-dimensional Echocardiography
Wang, Y., Gutman, J. M., Heilbron, D., Wahr, D., & Schiller, N. B. (1984) · Chest · doi:10.1378/chest.86.4.595 · Cited by 189
End points and clinical trial designs in pulmonary arterial hypertension
Hoeper, M. M., Oudiz, R. J., Peacock, A., Tapson, V. F., Haworth, S. G., Frost, A. E., & Torbicki, A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.010 · Cited by 170
Ng, L. L., Loke, I., Davies, J. E., Khunti, K., Stone, M., Abrams, K. R., Chin, D. T., & Squire, I. B. (2003) · European Journal of Heart Failure · doi:10.1016/s1388-9842(03)00154-5 · Cited by 53
Self-citation
Cited by
Diagnosis and Assessment of Pulmonary Arterial Hypertension
Badesch, D. B., Champion, H. C., Gomez Sanchez, M. A., Hoeper, M. M., Loyd, J. E., Manes, A., McGoon, M., Naeije, R., Olschewski, H., Oudiz, R. J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.011 · Cited by 1,138
Molecular pathogenesis of pulmonary arterial hypertension
Rabinovitch, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33452 · Cited by 880
van de Veerdonk, M. C., Kind, T., Marcus, J. T., Mauritz, G.-J., Heymans, M. W., Bogaard, H.-J., Boonstra, A., Marques, K. M. J., Westerhof, N., & Vonk-Noordegraaf, A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.068 · Cited by 846
Risk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
van Wolferen, S. A., Marcus, J. T., Boonstra, A., Marques, K. M. J., Bronzwaer, J. G. F., Spreeuwenberg, M. D., Postmus, P. E., & Vonk-Noordegraaf, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl477 · Cited by 753
Metadata
- Authors
- Wilkins, M. R., Paul, G. A., Strange, J. W., Tunariu, N., Gin-Sing, W., Banya, W. A., Westwood, M. A., Stefanidis, A., Ng, L. L., Pennell, D. J., Mohiaddin, R. H., Nihoyannopoulos, P., & Gibbs, J. S. R.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-01
- Volume
- 171
- Issue
- 11
- Pages
- 1292-1297
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2121688503
- Cited by
- 380
- References
- 33
- FWCI
- 32.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.